ReviewJournal of advanced research2017
Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy - A review.
Review in Journal of advanced research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 35 citations in OpenAlex.
- Knowledge, attitude, and practice toward hyperuricemia among healthcare workers in Shandong, China.PeerJ · 2024Article
- Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study.Biomedicines · 2023Article
- Lifestyle-Related Risk Factors for the Incidence and Progression of Chronic Kidney Disease in the Healthy Young and Middle-Aged Population.Nutrients · 2022Review
- Hyperuricemia, the heart, and the kidneys - to treat or not to treat?Renal failure · 2020Review
- Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy.Drugs - real world outcomes · 2020Article
- Approximate Mortality Risks between Hyperuricemia and Diabetes in the United States.Journal of clinical medicine · 2019Article
- Treatment of asymptomatic hyperuricemia complicated by renal damage: a controversial issue.International urology and nephrology · 2019Review
- Physicians' perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease: A questionnaire survey.Kidney research and clinical practice · 2019Article
- Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis.International urology and nephrology · 2019Article
- Effect of a Health Belief Model-based education program on patients' belief, physical activity, and serum uric acid: a randomized controlled trial.Patient preference and adherence · 2018Article
- Asymptomatic hyperuricemia: is it time to intervene?Clinical rheumatology · 2017Review
- The grey zone of Hyperuricemia in chronic kidney disease.Journal of advanced research · 2017Article
- Allopurinol Effects on Residual Renal Function in End-Stage Renal Disease Patients Undergoing Peritoneal Dialysis: Randomized Controlled Trial.Journal of research in pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asymptomatic hyperuricemia is increasing in prevalence. There is a growing body of literature suggesting that uric acid has deleterious effects on vascular health and renal histological integrity. Several trials, reviewed herein, suggest that lowering the serum uric acid level is associated with a slowing in the rate of renal deterioration in those with chronic kidney disease. Given that there is little available in the general armamentarium to slow the rate of kidney deterioration, strong consideration could be given to the administration of agents or lifestyle changes that decrease uric acid production in hyperuricemic patients with deteriorating kidney function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.